In the last 10 years, further indications were approved in different subsets of melanoma either as a monotherapy or as a combination therapy with nivolumab, like in B-Raf Proto-Oncogene (BRAF) V600 wild-type unresectable or metastatic melanoma [10]. This evidence concerns the gene BRAF and metastatic melanoma.